Last Modified: March 21, 2014
Dates: June 6, 2014
Location: Smilow Center for Translational Research Auditorium, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd., Philadelphia, PA 19104
Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania
Web Page URL: penncancer.org/CME/Brain
Topics Covered: Minimally Invasive Skull-Base Surgery Radiation Therapy: Proton, Stereotactic Intensity Modulated, Cyber/Gamma Knife Systemic and Targeted Therapies Treatment of Metastatic Brain Tumors Functional Imaging Survivorship: Seizure Management and Neurocognition Anti-angiogenesis Personalized Diagnostics Clinician's Perspective of Precision Medicine Immunotherapy Clinical Trials T-Cell Immunotherapy for Brain Tumors Vaccines New Drug Discovery
Objectives: Upon completion of this symposium, participants should be able to:
Who Should Attend: This symposium is designed for neurosurgeons, neuro-oncologists, neurologists, radiologists, medical oncologists, radiation oncologists, pathologists, neuropsychologists, primary care physicians, oncology nurses, and other healthcare professionals involved in the treatment of patients with brain tumors.
Registration Information: To request a brochure, please contact Mary M. Graham at firstname.lastname@example.org
Fees: $50 Practicing Physician; $25 non-Penn resident, fellow, nurse, and other healthcare professional; $25 faculty, staff, resident, fellow and/or student of the University of Pennsylvania
Continuing Education: Yes
Miscellany: The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Sep 29, 2011 - For patients with breast cancer and polysomy 17, the true gene status of human epidermal growth factor receptor 2 (HER2) can be effectively determined by use of additional chromosome 17 fluorescent in situ hybridization studies for Smith-Magenis syndrome, retinoic acid receptor alpha, and tumor protein p53 genes, rather than the HER2-to-centromeric probe ratio, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Jul 2, 2014
Jun 3, 2014
May 2, 2014
Apr 2, 2014
Mar 4, 2014
Feb 4, 2014